Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-15
2010-11-16
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S232800, C514S253050, C514S307000, C544S128000, C544S363000, C546S139000, C546S148000
Reexamination Certificate
active
07833999
ABSTRACT:
The invention relates to tetrahydroisoquinoline sulfonamide compounds (of formula (1) as defined in the specification), their preparation and their use in therapies for the treatment of central nervous system diseases such as vigilance and sleep disorders, narcolepsy, Alzheimer's disease and other dementias, Parkinson's disease, attention disorders in hyperkinetic children, memory and learning disorders, epilepsy, schizophrenia, moderate cognitive disorders, depression, anxiety, sexual dysfunction, dizziness and travel sickness.
REFERENCES:
patent: 5602145 (1997-02-01), Samanen
patent: 5798352 (1998-08-01), Danilewicz
patent: 7678807 (2010-03-01), Diaz Martin et al.
patent: 2008/0261999 (2008-10-01), Martin
patent: 1 070 714 (2001-01-01), None
patent: 1 679 309 (2006-07-01), None
patent: WO 00/71507 (2000-11-01), None
patent: WO 02/053558 (2002-07-01), None
patent: WO 02/076925 (2002-10-01), None
patent: WO 03/055848 (2003-07-01), None
patent: WO 03/076527 (2003-09-01), None
patent: WO 2004/019935 (2004-03-01), None
patent: WO 2005/035514 (2005-04-01), None
patent: WO 2006/018308 (2006-02-01), None
patent: WO 2006/018309 (2006-02-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Korte, et al, Characterization and tissue Distribution of H3 Histamine Receptors in Guinea Pigs by Nalpha-Methylhistamine, Biochemical and Biophysical Research Communications, (1990) 168(3), pp. 979-986.
Lovenberg, et al, Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles, JPET (2000) 293, pp. 771-778.
Tozer, et al, Histamine H3 Receptor Antagonists, Exp. Opin. Ther. Patents (2000) 10(7), pp. 1045-1055.
West, et al, Identification of Two H3-Histamine Receptor Subtypes, Molecular Pharmacology, 38, pp. 610-613, 1990.
Grunewald et al, Examination of the Role of the Acidic Hydrogen in Imparting Selectivity of 7-(Aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) Toward Inhibition of Phenylethanolamine N-Methyltransferase vs the alpha2-Adrenoceptor, J. Med. Chem., 1997 (40) pp. 3997-4005.
Katritzky et al, 2-Substituted-1,2,3,4-tetrahydroisoquinolines and chiral 3-carboxyl analogues from N-benzotriazolylmethyl-N-phenethylamines, Tetrahedron: Asymmetry, 2001 (12) pp. 2427-2434.
Liu et al, Does the [3H]Mepyramine Binding Site Represent the Histamine H1 Receptor? Re-examination of the Histamine H1 Receptor with Quinine, JPET, 1994 (268) 2, pp. 959-964.
Vippagunta et al., Crystalline solids, Advanced Drug Delivery Reviews, 2001 (48), pp. 3-26.
Diaz Martin Juan Antonio
Jimenez Bargueno Maria Dolores
Bender Kelly L.
Davis Zinna N
Newman Irving
sanofi-aventis
LandOfFree
Tetrahydroisoquinoline sulfonamide derivatives, the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydroisoquinoline sulfonamide derivatives, the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydroisoquinoline sulfonamide derivatives, the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4213186